Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 2/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.55 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556 | 0.98 | SNCA (0.65) | SNCALMNAL3MBTL1F2PRSS1 | |
| Naphthalene SCHEMBL28216326 | 0.98 | SNCA (0.65) | SNCALMNAL3MBTL1F2PRSS1 | |
| SCHEMBL28275730 | 0.98 | SNCA (0.65) | SNCALMNAL3MBTL1F2PRSS1 | |
| SCHEMBL29357423 | 0.98 | SNCA (0.65) | SNCALMNAL3MBTL1F2PRSS1 | |
| SCHEMBL304050 | 0.98 | SNCA (0.65) | SNCALMNAL3MBTL1F2PRSS1 | |
| SCHEMBL29857297 | 0.98 | SNCA (0.65) | SNCALMNAL3MBTL1F2PRSS1 | |
| SCHEMBL1032818 | 0.96 | SNCA (0.62) | SNCALMNAL3MBTL1F2PRSS1 | |
| SCHEMBL1177404 | 0.96 | SNCA (0.62) | SNCALMNAL3MBTL1F2PRSS1 | |
| SCHEMBL2880576 | 0.96 | SNCA (0.62) | SNCALMNAL3MBTL1F2PRSS1 | |
| Ammonia Solution, Strong SCHEMBL3845768 | 0.96 | SNCA (0.62) | SNCALMNAL3MBTL1F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104543972-A | Food colorant and preparing method thereof | NANTONG SHUANGHE FOOD CO LTD | 2015-04-29 | — | — | CN | claimed |
| US-20260097025-A1 | AMLODIPINE FORMULATIONS | AZURITY PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12383498-B2 | Amlodipine formulations | AZURITY PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4585213-A2 | AMLODIPINE FORMULATIONS | Silvergate Pharmaceuticals, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12336984-B2 | Amlodipine formulations | AZURITY PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20240390347-A1 | AMLODIPINE FORMULATIONS | AZURITY PHARMACEUTICALS, INC. | 2024-11-28 | — | — | US | disclosed |
| US-12053461-B2 | Amlodipine formulations | AZURITY PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240252433-A1 | AMLODIPINE FORMULATIONS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-08-01 | — | — | US | disclosed |
| US-11918685-B2 | Amlodipine formulations | AZURITY PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230338287-A1 | AMLODIPINE FORMULATIONS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2023-10-26 | — | — | US | disclosed |
| WO-2004000226-A2 | LIPOSOMES CONTAINING BIOLOGICALLY ACTIVE COMPOUNDS | PIEDMONT PHARMACEUTICALS, LLC (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030235610-A1 | Liposomes containing biologically active compounds | PIEDMONT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| EP-0370491-B1 | Liposome comprising a novel phosphate as membrane constituent, liposome preparations and cosmetic preparations comprising said phosphate | KAO CORP (JP) | 1995-04-19 | — | — | EP | disclosed |
| US-5153000-A | Moisture retaining | KAO CORPORATION (JP) | 1992-10-06 | — | — | US | disclosed |
| EP-0370491-A2 | Liposome comprising a novel phosphate as membrane constituent, liposome preparations and cosmetic preparations comprising said phosphate | KAO CORPORATION (JP) | 1990-05-30 | — | — | EP | disclosed |
| US-4263201-A | ORGANIC ACID METAL SALT, HALOGEN COMPOUND | GENERAL ELECTRIC COMPANY (US) | 1981-04-21 | — | — | US | disclosed |
| US-4251521-A | HYPOGLYCEMIC AGENTS | SANDOZ, INC. (US) | 1981-02-17 | — | — | US | disclosed |
| US-4251434-A | ORGANIC SALTS OF ALKALINE AND ALKALINE EARTH METALS | GENERAL ELECTRIC COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
| US-4110299-A | INORGANIC HALIDE, SULFONATE | GENERAL ELECTRIC COMPANY (US) | 1978-08-29 | — | — | US | disclosed |
| US-4104253-A | HALOGENATED ORGANIC ALKALI OR ALKALINE EARTH METAL SALTS | GENERAL ELECTRIC COMPANY (US) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252433-A1 | AMLODIPINE FORMULATIONS | CACNA1D, CAD, CACNA1C | SNCA 4516/4885LMNA 238/4885L3MBTL1 4101/4885 |
| US-20260097025-A1 | AMLODIPINE FORMULATIONS | CACNA1D, HCN4, SMYD3 | SNCA 893/4885LMNA 333/4885L3MBTL1 3954/4885 |
| US-12336984-B2 | Amlodipine formulations | CACNA1D, CAD, CACNA1C | SNCA 4601/4885LMNA 260/4885L3MBTL1 4205/4885 |
| US-11918685-B2 | Amlodipine formulations | CACNA1D, CAD, CACNA1C | SNCA 4516/4885LMNA 238/4885L3MBTL1 4101/4885 |
| US-20230338287-A1 | AMLODIPINE FORMULATIONS | CACNA1D, CAD, CACNA1C | SNCA 4516/4885LMNA 238/4885L3MBTL1 4101/4885 |
| US-12053461-B2 | Amlodipine formulations | CACNA1D, CAD, CACNA1C | SNCA 4601/4885LMNA 260/4885L3MBTL1 4205/4885 |
| US-20240390347-A1 | AMLODIPINE FORMULATIONS | CACNA1D, CAD, CACNA1C | SNCA 4601/4885LMNA 260/4885L3MBTL1 4205/4885 |
| US-12383498-B2 | Amlodipine formulations | CACNA1D, CAD, CACNA1C | SNCA 4516/4885LMNA 238/4885L3MBTL1 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.